Shares of Ziopharm Oncology (ZIOP +18.2%) post double-digit gains.
The company presented today at the Biotech Industry Conference in New York.
In the presentation, ZIOP says it is "the farthest advanced at regulating gene function in vivo in humans" and notes that it expects to have "at least 8 INDs through 2015."
The company also says data is set to be presented "near-term" at multiple conferences. (full presentation)